Response and Adherence to Nilotinib in Daily Practice

Trial Profile

Response and Adherence to Nilotinib in Daily Practice

Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms RAND
  • Most Recent Events

    • 25 Aug 2014 According to Netherlands Trial Registry record, Status changed from not yet recruiting to recruiting.
    • 28 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top